Hem/Onc Library - Page 2 of 25 - SOHO Insider

Skip to content

Long hours, poor management contribute to high burnout in heme professionals
Early-data support glofitamab combo in high-risk LBCL
Dr. Masarova discusses SURPASS-ET study at EHA 2025
The journey of belantamab mafodotin in multiple myeloma
Vitamin D supplementation does not improve DLBCL outcomes

Join SOHO

Follow Us :

Insider Podcast
About
Society Updates
- Society Updates
- Join SOHO
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
  - MDS Roundtable
  - MPN Roundtable
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

FDA removes REMS requirement for 6 CAR-T therapies

Cellular Therapy

FDA removes REMS requirement for 6 CAR-T therapies

Leukemia

FDA removes REMS requirement for 6 CAR-T therapies

Lymphoma

FDA removes REMS requirement for 6 CAR-T therapies

Multiple Myeloma

FDA removes REMS requirement for 6 CAR-T therapies

Myelodysplastic Syndromes

FDA removes REMS requirement for 6 CAR-T therapies

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

July 10, 2025

Insider Podcast
About
Society Updates
- Society Updates
- Join SOHO
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
  - MDS Roundtable
  - MPN Roundtable
- Video Interviews
Subscribe

SOHO Insider Hem/Onc Library

Leukemia Lymphoma Multiple Myeloma

FDA removes REMS requirement for 6 CAR-T therapies

by Leah Sherwood
June 27, 2025
0 Comments

Flipping of sheets of calendar with black and red numbers

18-IMCL News

ELARA trial: tisagenlecleucel response extends to 4 years in follicular lymphoma

by SOHO Insider Editors
June 26, 2025
0 Comments

SOHO Insider podcast

Leukemia Acute Myeloid Leukemia News SOHO Insider Podcast

Inside AML challenges with Drs. Jabbour, Daver

by Leah Sherwood
June 25, 2025
0 Comments

SOHO Insider

EHA 2025

Dr. Komrokji reports imetelstat data in high-EPO MDS from EHA 2025

by Leah Sherwood
June 24, 2025
0 Comments

GGM ASCO/EHA

2025 ASCO Video Interviews

Latest COMMANDS analysis shows luspatercept is transformative in MDS

by Leah Sherwood
June 24, 2025
0 Comments

Idoroenyi Amanam

2025 ASCO Video Interviews

Idoroenyi Amanam, MD, discusses real-world study of luspatercept in LR-MDS

by SOHO Insider Editors
June 23, 2025
0 Comments

18-IMCL News

GOLSEEK-1 phase 3 study of golcadomide for untreated LBCL

by SOHO Insider Editors
June 22, 2025
0 Comments

A scientific and medical concept focused on the microbiome, gut health, and microbiotic cells. The image highlights laboratory research, medicine, nutrition, and the role of probiotics like yogurt.

18-IMCL Lymphoma

Gut-linked microbes tied to survival in DLBCL

by Leah Sherwood
June 20, 2025
0 Comments

radiotherapy

18-IMCL Lymphoma

‘Boom Boom’ Radiotherapy approach may boost CAR T-cell responses

by Leah Sherwood
June 18, 2025
0 Comments

3D rendering of genetically modified cells expressing chimeric antigen receptor for CAR Tcell therapy. Concept Biotechnology, Genetic Engineering, Cancer Immunotherapy, Medical Illustration

EHA 2025

B-ALL patients refractory to brexu-cel face poor survival outcomes

by SOHO Insider Editors
June 17, 2025
0 Comments

Load More

Top Categories

$B-ALL patients refractory to brexu-cel face poor survival outcomes$

Cellular Therapy

12

$B-ALL patients refractory to brexu-cel face poor survival outcomes$

Leukemia

43

$B-ALL patients refractory to brexu-cel face poor survival outcomes$

Lymphoma

44

$B-ALL patients refractory to brexu-cel face poor survival outcomes$

Multiple Myeloma

31

$B-ALL patients refractory to brexu-cel face poor survival outcomes$

Myelodysplastic Syndromes

13

$B-ALL patients refractory to brexu-cel face poor survival outcomes$

Myeloproliferative Neoplasms

10

POPULAR NEWS

Leukemia , Lymphoma , Multiple Myeloma , Myelodysplastic Syndromes , Myeloproliferative Neoplasms , News , Society Updates

Abstract submissions now open for SOHO 2025

February 14, 2025

Imatinib

66th American Society of Hematology Annual Meeting & Exposition , Leukemia

Asciminib benefit-risk profile bests other TKIs in CML

December 10, 2024

MyeloMatch, NCI

Leukemia , Acute Myeloid Leukemia , Myelodysplastic Syndromes

NCI’s myeloMATCH pushes the envelope in myeloid leukemia care

January 3, 2025

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Categories

FDA removes REMS requirement for 6 CAR-T therapies

Cellular Therapy

FDA removes REMS requirement for 6 CAR-T therapies

Leukemia

FDA removes REMS requirement for 6 CAR-T therapies

Lymphoma

FDA removes REMS requirement for 6 CAR-T therapies

Multiple Myeloma

FDA removes REMS requirement for 6 CAR-T therapies

Myelodysplastic Syndromes

FDA removes REMS requirement for 6 CAR-T therapies

Myeloproliferative Neoplasms

Subscribe

Recent Posts

SOHO Insider

Long hours, poor management contribute to high burnout in heme professionals

T cell or B cell

Early-data support glofitamab combo in high-risk LBCL

Dr. Masarova discusses SURPASS-ET study at EHA 2025

Copyright © 2025 Society of Hematologic Oncology, All rights reserved.